ANI Pharmaceuticals, Inc. (ANIP) is a reputable pharmaceutical company with a long-standing history of developing high-quality branded and generic prescription drugs. Incorporated in Minnesota, ANIP operates with a commitment to patient health, serving a broad range of major markets within the healthcare sector. The company focuses on delivering robust and efficient products while maintaining the highest standards of integrity, compliance, and corporate governance.
ANI Pharmaceuticals' diverse product portfolio comprises a wide variety of therapeutic options catering to numerous patient needs. These include medicines for cardiovascular diseases, neuroscience, and men's and women's health, among others. What sets ANIP apart is its penchant for exploring unmet medical needs and providing innovative solutions to meet these needs.
Coupled with a robust development pipeline, the company consistently develops new, innovative products and seeks to bring these to market, leveraging their strong relationships within the industry and their ongoing investment in research and development. This unwavering commitment to innovation and growth is what makes ANIP a leader in its field.
ANIP is proud of its manufacturing capabilities, operating state-of-the-art facilities that strictly adhere to FDA standards, ensuring patient safety and consistent product quality. The company, with its exceptional quality control and assurance systems, is heavily invested in producing reliable, effective, and safe products for patients across different demographics.
Aside from conducting its own R&D and manufacturing, ANIP also has a footing in contract manufacturing and pharmaceutical packaging. The company offers comprehensive solution development, from ideation to launch, for entities seeking to bring their products to market. This side of the business expands ANIP's reach and influence in the industry.
In the financial market, ANIP trades on the NASDAQ Global Select Market, indicating the company's strong financial performance and corporate governance. Shareholders have continued to support ANIP due to its strategy of sustainable growth and its success in delivering solid financial results.
ANI Pharmaceuticals’ strong leadership team with extensive experience in the pharmaceutical industry plays an integral role in its success. This leadership, combined with a dedicated, forward-thinking employee base, fuels ANIP's continued growth in an ever-evolving healthcare landscape.
In conclusion, ANI Pharmaceuticals, Inc. is a high-performing pharmaceutical enterprise known for its unwavering commitment to patient health and product quality, pioneering R&D initiatives, robust product pipeline, and first-rate manufacturing facilities. Through its multifaceted operations and effective strategies, ANIP continues to strengthen its standing as a leader in the pharmaceutical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Bank of America Corp DE has acquired 183,066 shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), valued at approximately $15.2 million, giving them a 0.80% stake in the company. Other institutional investors have also increased their holdings, with institutional investors now owning 76.05% of the company's stock. Despite recent insider selling, ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 EPS on $266.04 million in revenue, and has issued fiscal 2026 EPS guidance of $9.19–$9.69.
Oppenheimer has initiated coverage of ANI Pharmaceuticals (ANIP) with a "Perform" rating and an $85 price target. The company currently has an average analyst rating of "overweight" and a mean price target of $105.78 from other analysts.
Nikhil Lalwani, President & CEO of ANI Pharmaceuticals (ANIP), sold 5,400 shares on September 15, 2026, bringing his total sales over the past year to 65,800 shares with no purchases. This insider selling trend is notable, especially as the company's stock is considered "Modestly Undervalued" by GuruFocus, with a price-to-earnings ratio lower than the industry median and its historical median. While insider selling can occur for various reasons, the absence of insider buys and the trimming of positions by most gurus holding the stock add a cautious element for investors.
ANI Pharmaceuticals (NASDAQ:ANIP) CEO Nikhil Lalwani sold 5,400 shares of the company's stock for $383,400.00 on September 15th, reducing his stake by 1.57%. This transaction occurred under a pre-arranged Rule 10b5-1 plan. The company recently reported strong quarterly earnings, exceeding analyst expectations, and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $105.57.
Cook Meredith, Senior VP, General Counsel & Secretary at ANI Pharmaceuticals (NASDAQ: ANIP), sold 500 shares of the company stock on September 14, 2026, at a price of $70.79 per share. Following this transaction, Meredith retains 73,924 shares. The sale represented approximately 0.7% of Meredith's previous holdings, providing transparency on the scale of the disposal.